SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

VK2735

VKTX·Viking Therapeutics, Inc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 3
Time to market
Unknown; Phase 3 trials (SUNRISE-1/2) were initiated October 2026. If successful, potential FDA submission could come in 2028-2029 at the earliest, barring accelerated development.
Why 4/10
VK2735 has no pending PDUFA or regulatory decision; Phase 3 topline readouts (SUNRISE-1/2) were just initiated Oct 2026 and are likely 18-24+ months away. The next dated catalyst is the Q3 2026 earnings call on Oct 28, 2026, which is a routine event, not a binary clinical catalyst. Without a hard near-term binary, the impactScore is capped at 5 despite VK2735 being the company's lead asset.
Actionable Insight NEUTRAL

The key near-term catalyst is Q3 2026 earnings on Oct 28, 2026, where management may provide Phase 3 timeline updates. The Phase 3 SUNRISE-1/2 trials were just initiated in Oct 2026, so topline data is likely 18-24+ months away. With the stock at ~$24.40 near 52-week lows and the mean analyst target at ~$95, the risk/reward hinges on whether Phase 3 data mirrors the strong Phase 2 results, but significant capital dilution (~$575M raise in Sept 2026) has already weighed on shares.

Price Chart

Loading chart...

Executive Summary

VK2735 is Viking Therapeutics' lead asset, a dual GLP-1/GIP receptor agonist for obesity, the same mechanism as Eli Lilly's tirzepatide (Zepbound). The drug showed promising Phase 2 results and has now advanced to an oral Phase 3 program (SUNRISE-1 and SUNRISE-2 studies), initiated in October 2026. Viking raised ~$575M in September 2026 to fund this development. The stock trades at ~$24.40, near its 52-week low, with analysts uniformly bullish (mean target ~$95). However, VK2735 faces a long development timeline (Phase 3 readouts ~2 years away), intense competition from established blockbusters, high short interest (~20.6% of shares outstanding), and recent shareholder dilution from the capital raise.

How It Works

VK2735 is a dual GLP-1/GIP receptor agonist, it mimics two natural gut hormones (GLP-1 and GIP) that help regulate blood sugar and suppress appetite. This is the same mechanism as Eli Lilly's blockbuster obesity drug tirzepatide (Zepbound/Mounjaro). It is being developed in both an injectable (subcutaneous) and oral tablet formulation for chronic weight management in obesity.

Trial Status

VK2735 completed Phase 2 studies for obesity. In October 2026, Viking initiated the oral Phase 3 program (SUNRISE-1 evaluating oral VK2735 in obese adults without type 2 diabetes, SUNRISE-2 in those with type 2 diabetes) and a separate oral maintenance dosing trial. The company also has a subcutaneous formulation in earlier-stage development.

The Two-Sided Case

▲ Bull Case4
VK2735 is a dual GLP-1/GIP receptor agonist (same mechanism as Eli Lilly's blockbuster tirzepatide) that has already demonstrated promising Phase 2 weight-loss data, supporting an oral Phase 3 program (SUNRISE-1 and SUNRISE-2) initiated in October 2026.
Analyst consensus is overwhelmingly bullish: 23 Buy/Strong Buy ratings vs 3 Hold, zero Sells, with a mean price target of ~$95.05 against the current ~$24.40 stock price, implying roughly 290% upside.
The company raised ~$575M in gross proceeds in Sept 2026 specifically to fund VK2735's Phase 3 development and potential commercialization, removing near-term financing risk.
Major institutional holders include FMR LLC ($247M), BlackRock ($241M), and State Street ($219M) as of Q2 2026, with multiple funds like Jump Financial and BNP Paribas significantly adding to positions.
▼ Bear Case4
VK2735 enters a massive competitive market already dominated by Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro/tirzepatide), which target the same dual GLP-1/GIP mechanism, VK2735 will need to show best-in-class data to carve out market share.
The stock has fallen from $43.15 52-week high to $24.40 (near 52-week low) as of Oct 23, 2026, and a ~$575M capital raise via convertible notes and common stock in Sept 2026 has diluted existing shareholders significantly, with a $50.75/share note conversion price creating overhang.
Short interest is high at roughly 20.62% of estimated shares outstanding as of Sept 30, 2026, and the bull/bear evidence scan shows a net bearish signal with 16+ institutional exits/trims and ~$5M in insider sales by the CEO and CFO in July 2026.
Phase 3 topline data for the oral formulation is likely 2+ years away, providing no near-term binary catalyst. Any safety or efficacy miss versus tirzepatide would be devastating given the stock's premium valuation expectations.

Upcoming Catalysts

  • Q3 2026 earnings call on October 28, 2026, management may provide Phase 3 enrollment timelines and pipeline updates
  • Phase 3 SUNRISE-1/2 enrollment updates over the next 12-18 months
  • Potential data from the oral maintenance dosing trial initiated October 2026
  • Any partnership or licensing interest from larger pharma companies

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report

Sources · 7

Hover a chip for the title
1 prnewswire.com2 prnewswire.com3 prnewswire.com4 prnewswire.com5 prnewswire.com6 sec.gov7 sec.gov